The efficacy and safety of FSK0808, filgrastim biosimilar: A multicenter, non-randomized study in Japanese patients with breast cancer

Japanese Journal of Clinical Oncology

Volumn 43, Issue 9, 2013, Pages 865-873

  Sagara, Yoshiaki ^a   Sato, Kazuhiko ^b   Fukuma, Eisuke ^c   Higaki, Kenji ^d   Mizutani, Mitsuhiro ^e   Osaki, Akihiko ^f   Takano, Toshimi ^g   Tokuda, Yutaka ^h   Ohno, Shinji ⁱ   Masuda, Norikazu ^j   Suzuki, Masato ^k   Saeki, Toshiaki ^f  

^a SAGARA HOSPITAL   (Japan)

^b Tokyo West Tokushukai Hospital   (Japan)

^c KAMEDA MEDICAL CENTER   (Japan)

^d HIROSHIMA CITY HOSPITAL   (Japan)

^e Mikawa Breast Cancer Clinic   (Japan)

^f SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

^k TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

more..

Author keywords

Biosimilar; Breast cancer; Chemotherapy; Filgrastim; Neutropenia

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOSIMILAR AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FSK 0808; IMMUNOMODULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD TRANSFUSION; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EYE PAIN; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENITAL HERPES; GINGIVA PAIN; HEART PALPITATION; HOT FLUSH; HUMAN; JAPANESE; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OROPHARYNX PAIN; PERIPROCTITIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; UPPER ABDOMINAL PAIN;

BIOSIMILAR; BREAST CANCER; CHEMOTHERAPY; FILGRASTIM; NEUTROPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOSIMILAR PHARMACEUTICALS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG TOXICITY; EPIRUBICIN; FEMALE; FLUOROURACIL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; JAPAN; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; RECOMBINANT PROTEINS;

EID: 84883334647     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt091     Document Type: Article

References (21)

1. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31.
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
3. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53.
4. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62:1-15.
5. Martin-Christin F. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 2001;12:185-91.
6. Welke K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29.
7. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1998;318:1414-22.
8. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-13.
9. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5.
10. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-72.
11. Tominaga T, Abe R, Miura S, et al. Evaluation of KRN 8601 (rhG-CSF) on neutropenia induced by chemotherapy for advanced breast cancer. Biotherapy 1994;8:1503-16. (in Japanese).
12. Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996;14:35-45.
13. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 2001;19:4224-37.
14. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-11.
15. Leonard RC, Miles D, Thomas R, Nussey F. UK Breast Cancer Neutropenia Audit Group. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003;89:2062-8.
16. NCCN Guidelines Version 1. 2012 Myeloid Growth Factors [Internet]. Pennsylvania: National Comprehensive Cancer Network 2012. [cited 13 August 2012]. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf
17. Toi M, Nakamura S, Kuroi K, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat 2008;110:531-9.
18. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
19. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
20. Aso Y, Akaza H, Tazaki H, et al. Clinical study of KRN8601 (rhG-CSF) on leukopenia induced by chemotherapy for urogenital cancer. Jpn J Urol Surg 1990;3:677-86.
21. Aso Y, Akaza H, Kumamoto Y, et al. Phase III study of KRN8601 (rhG-CSF) on neutropenia induced by chemotherapy for transitional cell carcinoma of urinary tract. Jpn J Urol Surg 1994;7:189-99.